Designing CD4 immunoadhesins for AIDS therapy

A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.


Published in:
Nature, 337, 6207, 525-31
Year:
1989
ISSN:
0028-0836
Keywords:
Note:
Department of Molecular Biology, Genentech, Inc., South San Francisco, California 94080.
Laboratories:




 Record created 2007-06-05, last modified 2018-01-28

External link:
Download fulltext
URL
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)